Nuvation Bio Inc. has released a corporate presentation detailing recent developments in its oncology portfolio. The company highlighted the approval of IBTROZI® (taletrectinib), a next-generation ROS1 inhibitor, for advanced ROS1-positive non-small cell lung cancer (NSCLC) in the U.S., Japan, and China. Nuvation Bio also announced a strategic partnership with Eisai, granting Eisai exclusive rights to develop, register, and commercialize IBTROZI in Europe and additional territories outside the U.S., China, and Japan. The agreement includes an upfront payment of approximately $60 million, a near-term milestone payment of around $30 million upon conditional or full approval in Europe, and double-digit tiered royalties on net sales. In addition, the company is advancing safusidenib, a brain-penetrant mIDH1 inhibitor, in a pivotal study for high-grade and high-risk IDH1-mutant glioma. Nuvation Bio is also developing NUV-868, a BD2-selective BET inhibitor, and evaluating preclinical candidates from its proprietary Drug-Drug Conjugate $(DDC)$ platform. The presentation noted a robust pro forma cash balance of approximately $589 million, with access to an additional $50 million under a term loan facility. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.